High expression of guanine nucleotide-binding protein-like-3-like is associated with poor prognosis in esophageal cancer.
Aged
Antineoplastic Combined Chemotherapy Protocols
/ therapeutic use
Biomarkers, Tumor
/ analysis
Cell Nucleus
/ pathology
Cell Proliferation
Chemotherapy, Adjuvant
/ methods
Cytoplasm
/ pathology
Esophageal Neoplasms
/ genetics
Esophageal Squamous Cell Carcinoma
/ genetics
Esophagectomy
Esophagus
/ cytology
Female
GTP-Binding Proteins
/ analysis
Gene Expression Regulation, Neoplastic
Humans
Immunohistochemistry
Male
Middle Aged
Nuclear Proteins
/ analysis
Prognosis
Up-Regulation
Journal
Medicine
ISSN: 1536-5964
Titre abrégé: Medicine (Baltimore)
Pays: United States
ID NLM: 2985248R
Informations de publication
Date de publication:
28 May 2021
28 May 2021
Historique:
received:
15
11
2020
accepted:
28
04
2021
entrez:
25
5
2021
pubmed:
26
5
2021
medline:
4
6
2021
Statut:
ppublish
Résumé
Guanine nucleotide-binding protein-like-3-like (GNL3L) is required for processing ribosomal pre-rRNA and cell proliferation and is upregulated in many types of cancer. This study is aimed to investigate the clinical significance of GNL3L in esophageal cancer. The mRNA and protein expression levels of GNL3L were determined by using quantitative real-time polymerase chain reaction and immunohistochemistry, respectively. GNL3L was localized in both cytoplasm and nucleus. The expression levels of GNL3L in esophageal cancer tissues were significantly higher than those in adjacent nonmalignant tissues. High GNL3L expression was associated with pathologic type and poor differentiation. Patients with high GNL3L expression had shorter overall survival (OS) than those with low GNL3L expression. Multivariate Cox regression analysis revealed that GNL3L expression was an independently predictive factor for the OS of patient with esophageal cancer. The Gene Expression Profiling Interactive Analysis (GEPIA) databases also showed that GNL3L was upregulated in esophageal cancer, which was closely associated with an unfavorable prognosis of patients with esophageal cancer. Taken together, our findings suggest that GNL3L is upregulated in esophageal cancer, which is linked to the progression of the disease. As a result, GNL3L could be used as a biomarker for esophageal cancer.
Identifiants
pubmed: 34032716
doi: 10.1097/MD.0000000000025993
pii: 00005792-202105280-00026
pmc: PMC8154413
doi:
Substances chimiques
Biomarkers, Tumor
0
GNL3L protein, human
0
Nuclear Proteins
0
GTP-Binding Proteins
EC 3.6.1.-
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
e25993Subventions
Organisme : the Scientific Research Project Foundation of Health Department, Jiangsu, China
ID : H2017075
Organisme : the Innovation Team Project Foundation of Taizhou People's Hospital
ID : CXTDB201904
Organisme : the Foundation of Jiangsu Provincial Medical Innovation Team
ID : CXTDA2017042
Informations de copyright
Copyright © 2021 the Author(s). Published by Wolters Kluwer Health, Inc.
Déclaration de conflit d'intérêts
The authors have no conflicts of interest to disclose.
Références
Bray F, Ferlay J, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021.
Zheng RS, Sun KX, Zhang SW, et al. [Report of cancer epidemiology in China, 2015]. Zhonghua Zhong Liu Za Zhi 2019;41:19–28.
Du X, Rao MR, Chen XQ, Wu W, Mahalingam S, Balasundaram D. The homologous putative GTPases Grn1p from fission yeast and the human GNL3L are required for growth and play a role in processing of nucleolar pre-rRNA. Mol Biol Cell 2006;17:460–74.
Thoompumkal IJ, Subba Rao MR, Kumaraswamy A, Krishnan R, Mahalingam S. GNL3L is a nucleo-cytoplasmic shuttling protein: role in cell cycle regulation. PLoS one 2015;10:e0135845.
Thoompumkal IJ, Rehna K, Anbarasu K, Mahalingam S. Leucine Zipper Down-regulated in Cancer-1 (LDOC1) interacts with guanine nucleotide binding protein-like 3-like (GNL3L) to modulate nuclear factor-kappa B (NF-κB) signaling during cell proliferation. Cell cycle (Georgetown, Tex) 2016;15:3251–67.
Meng L, Hsu JK, Tsai RY. GNL3L depletion destabilizes MDM2 and induces p53-dependent G2/M arrest. Oncogene 2011;30:1716–26.
Kannathasan T, Kuo WW, Chen MC, et al. Chemoresistance-associated silencing of miR-4454 promotes colorectal cancer aggression through the GNL3L and NF-κB pathway. Cancers 2020;12:1231.
Okamoto N, Yasukawa M, Nguyen C, et al. Maintenance of tumor initiating cells of defined genetic composition by nucleostemin. Proc Natl Acad Sci U S A 2011;108:20388–93.
Jiang L, Wang W, Li G, et al. High TUG1 expression is associated with chemotherapy resistance and poor prognosis in esophageal squamous cell carcinoma. Cancer Chemother Pharmacol 2016;78:333–9.
Zhang X, He C, He C, et al. Nuclear PKM2 expression predicts poor prognosis in patients with esophageal squamous cell carcinoma. Pathol Res Pract 2013;209:510–5.
Kosvyra A, Maramis C, Chouvarda I. Developing an integrated genomic profile for cancer patients with the use of NGS data. Emerg Sci J 2019;3:157–67.
Tang Z, Li C, Kang B, Gao G, Li C, Zhang Z. GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res 2017;45:W98–102.
Szklarczyk D, Morris JH, Cook H, Kuhn M, Wyder S. The STRING database in 2017: quality-controlled protein-protein association networks, made broadly accessible. Nucleic Acids Res 2017;45:D362–8.
Rao MR, Kumari G, Balasundaram D, Sankaranarayanan R, Mahalingam S. A novel lysine-rich domain and GTP binding motifs regulate the nucleolar retention of human guanine nucleotide binding protein, GNL3L. J Mol Biol 2006;364:637–54.
Multhoff G, Molls M, Radons J. Chronic inflammation in cancer development. Front Immunol 2011;2:98.
Sell S. On the stem cell origin of cancer. Am J Pathol 2010;176:2584–3494.
Clarke MF. Clinical and therapeutic implications of cancer stem cells. N Engl J Med 2019;380:2237–45.
Kreso A, Dick JE. Evolution of the cancer stem cell model. Cell Stem Cell 2014;14:275–91.
Chae YC, Kim JH. Cancer stem cell metabolism: target for cancer therapy. BMB reports 2018;51:319–26.
De Angelis ML, Francescangeli F, Zeuner A. Breast cancer stem cells as drivers of tumor chemoresistance, dormancy and relapse: new challenges and therapeutic opportunities. Cancers 2019;11:1569.
Agliano A, Calvo A, Box C. The challenge of targeting cancer stem cells to halt metastasis. Semin Cancer Biol 2017;44:25–42.
Trevellin E, Pirozzolo G, Fassan M, Vettor R. Prognostic value of stem cell markers in esophageal and esophagogastric junction cancer: a meta-analysis. J Cancer 2020;11:4240–9.